Understanding Biomarker Method Validation: Establishing Quantitative Ranges – A Scientific Perspective

Introduction

The January 2025 FDA Biomarker Assay Validation guidance suggests using PK validation approaches as a starting point. However, our extensive experience shows why quantitative range determination for biomarker assays demands a fundamentally different scientific approach.

The Traditional Drug Assay Paradigm

In drug concentration assays, establishing quantitative ranges follows a straightforward path: analysts confirm ranges through accuracy and precision measurements at independently spiked target LLOQ and ULOQ levels. This works because they’re measuring a well-characterized drug product used to create their calibration standards.

The Scientific Challenge of Biomarker Assays

Biomarker measurement presents a more complex scientific reality. Instead of working with spiked samples of a known reference standard, we must determine ranges based on the behavior of endogenous molecules in actual biological samples. This fundamental difference demands a more sophisticated approach to range determination.

Scientific Approaches to Range Determination

LLOQ Establishment

Rather than relying on spiked samples, we must:

• Conduct parallelism evaluations across multiple individual samples containing endogenous analyte

• Identify the lowest concentration that can be reliably measured in these parallelism studies

• Consider how biological matrix complexity affects our ability to measure low concentrations consistently

ULOQ Determination

The upper range presents unique considerations:

• We set a provisional ULOQ based on the analytical performance of the calibrator material, but we must confirm with high-concentration endogenous analyte samples as they become available

• The range evolves as we analyze more biological samples and understand their concentration distribution

• Our ULOQ must reflect both analytical capabilities and biological relevance

Why This Matters

This scientifically driven approach ensures our quantitative ranges reflect not just analytical performance but meaningful biological measurements. It acknowledges that biomarker quantification must work reliably across the actual concentration ranges we encounter in clinical samples.